Over the past few months, I've been collaborating with @socialcapital (@chamath's investment vehicle) on a two-part deep dive into the current state of Longevity Biotech and Aging Research. This deep dive aims to be a solid introduction to the field. It assumes no background in biology, medicine, or biotech. If you've been wondering what science knows about aging, what makes us believe aging can be slowed or reversed, or which companies are making real progress toward developing therapies against aging, this is for you! Part 1 is out now. It's a foundation for understanding the biology of aging and the current state of longevity biotech. Part 2 follows shortly, covering the strategies researchers, companies, and investors are pursuing to slow or reverse aging. Thank you, @chamath and @socialcapital team, for the opportunity to work with you on it. And thank you to all contributors who helped to make this deep dive objective and engaging, and who are making anti-aging interventions a reality: @Andrei_Tarkhov, @elimohamad, @fedichev, @KarlPfleger, @MarkHamalainen, @MartinBJensen, @MaxUnfried, @mkaeberlein, @omri_drory, @RaianyRomanni, @realnathancheng, @sebastiangiwa, @shappiron, @shoylev, @statto, @strygah, @ydeigin If any errors are to be found in this deep dive, I own them.